|
業務類別
|
-- |
|
業務概覽
|
Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company's principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products,consumer health products, and medical devices in Canada, Latin America and select international markets . The company finances other life sciences companies across the globe in order to generate interest income, strengthen relationships inthe life sciences industry, and to secure product distribution rights. Geographically the company generates revenue from Brazil, Colombia, Argentina, Rest of LATAM, Canada, and Other, with the majority revenue generated from the Brazil region. |
| 公司地址
| 3400 De Maisonneuve West, Suite 1055, Montreal, QC, CAN, H3Z 3B8 |
| 電話號碼
| +1 514 484-4483 |
| 傳真號碼
| +1 514 481-4116 |
| 公司網頁
| https://www.gud-knight.com |
| 員工數量
| 745 |
| Mr. Leopoldo Bosano |
Global Vice President, Manufacturing and Operations |
-- |
04/04/2025 |
| Ms. Samira Sakhia |
Director, President and Chief Executive Officer |
-- |
04/04/2025 |
| Ms. Melanie Groleau |
Global Vice President, Medical and Clinical |
-- |
26/03/2025 |
| Ms. Amal Khouri |
Chief Business Officer |
-- |
04/04/2025 |
| Mr. Arvind Utchanah |
Chief Financial Officer |
-- |
04/04/2025 |
| Ms. Susan Emblem |
Global Vice President, Human Resources |
-- |
26/03/2025 |
| Mr. Henrique Dias |
Global Vice President, Marketing |
-- |
04/04/2025 |
| Ms. Monica Percario |
Global Vice President, Regulatory and Quality |
-- |
26/03/2025 |
|
|
| Mr. James C. Gale |
Lead Independent Director |
04/04/2025 |
| Mr. Robert N. Lande |
Independent Director |
04/04/2025 |
| Ms. Samira Sakhia |
Director, President and Chief Executive Officer |
04/04/2025 |
| Mr. Jonathan Ross Goodman |
Executive Chairman of the Board |
04/04/2025 |
| Mr. Michael J. Tremblay |
Independent Director |
04/04/2025 |
| Mr. Nicolas Sujoy |
Independent Director |
04/04/2025 |
| Ms. Janice Murray |
Independent Director |
04/04/2025 |
|
|
|
|
